Zytiga 250mg & 500 mg Tablet
PDF Leaflet Revision Date: 15 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of high-risk metastatic prostate cancer and metastatic castration-resistant prostate cancer.
Dosage (summary)
1 g daily (two 500 mg or four 250 mg tablets) on an empty stomach.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not for use in women.
Key Drug Interactions
- Strong CYP3A4 inducers
- Corticosteroids
Contraindications
- Hypersensitivity to abiraterone
- Moderate to severe hepatic impairment
- Pregnancy
- Women
Common side effects
- Hypokalaemia
- Hypertension
- Peripheral oedema
- Increased liver enzymes
Counselling Points
- Take on an empty stomach
- Monitor for liver function
- Use contraception during treatment
Serious warnings
- Hepatotoxicity
- Cardiovascular risks
- Mineralocorticoid excess
Important Disclaimer
The Zytiga 250mg & 500 mg Tablet professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
